Daewoong Pharmaceutical signs co-promotion agreement of ‘Foxiga & Xigduo’ with AstraZeneca
Daewoong Pharmaceutical(CEO Jong-Wook Lee) signed a co-promotional partnership agreement of ‘Forxiga(dapagliflozin)’ and ‘Xigduo(dapagliflozin+metformin),’ SGLT-2 inhibitors for the treatment of type 2 diabetes with AstraXeneca Korea(CEO Sang-Pyo Kim).
The agreement has taken a progress to exten...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
